0.5 mg retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial VisualAbstract: Retatrutide reduces body weight

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for glycaemic control in patients with type 2 diabetes, have demonstrated significant cardiometabolic benefits

The incidence of IIH is increasing and yet the underlying trigger and the fueling pathological mechanisms are still ...

Achieve safe, sustainable weight loss with personalized GLP-1 therapy at Aesthetics by Kallee in Palm Beach Gardensscience-based care that transforms confidence.

**Based on 9-hour acid control studies during the day and 12-hour acid control studies during the night

KACTUS provides a broad spectrum of high-quality recombinant proteins that are relevant to obesity therapeutic studies. including traditional targets like GDF8 and GLP-1R: Product Validation Data Immobilized Human Latent GDF-8, His Tag at 1 g/ml (100 l/well) on the plate